632 related articles for article (PubMed ID: 14626916)
21. . . . and Brazilian AIDS programme threatened by US trade action.
Int J Epidemiol; 2001 Apr; 30(2):413. PubMed ID: 11369751
[No Abstract] [Full Text] [Related]
22. WHO pulls Indian generics off AIDS drugs list.
Nat Med; 2004 Sep; 10(9):885. PubMed ID: 15340402
[No Abstract] [Full Text] [Related]
23. Indian company seeks US approval for generic AIDS drugs.
Nature; 2004 Aug; 430(7001):716. PubMed ID: 15306779
[No Abstract] [Full Text] [Related]
24. Drug patent protection: how long is long enough?
Sibbald B
CMAJ; 2001 May; 164(9):1331. PubMed ID: 11341146
[No Abstract] [Full Text] [Related]
25. Bills target biosimilar drugs.
Wadman M
Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
[No Abstract] [Full Text] [Related]
26. On access and accountability--two Supreme Court rulings on generic drugs.
Boumil MM; Curfman GD
N Engl J Med; 2013 Aug; 369(8):696-7. PubMed ID: 23923990
[No Abstract] [Full Text] [Related]
27. SuperGenerics: a better alternative for biogenerics.
Charles SA
Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591
[No Abstract] [Full Text] [Related]
28. FDA's proposed rules on patent listing requirements for new drug and 30-month stays on ANDA approval (proposed Oct. 24, 2002).
Hui YF
Ann Health Law; 2003; 12(2):325-40, table of contents. PubMed ID: 12856462
[TBL] [Abstract][Full Text] [Related]
29. Action alert: drug-patent bill could cost patients $3 billion+; hearing July 1.
AIDS Treat News; 1999 Jun; (No 321):8. PubMed ID: 11366716
[TBL] [Abstract][Full Text] [Related]
30. The ongoing regulation of generic drugs.
Frank RG
N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
[No Abstract] [Full Text] [Related]
31. Countering delays in introduction of generic drugs.
Lancet; 2002 Jan; 359(9302):181. PubMed ID: 11812545
[No Abstract] [Full Text] [Related]
32. Intellectual property. Balancing innovation and access: patent challenges tip the scales.
Higgins MJ; Graham SJ
Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944
[No Abstract] [Full Text] [Related]
33. Health policy or intellectual property policy? The fight over Bill C-91. Canadian Healthcare Association.
Int J Health Care Qual Assur Inc Leadersh Health Serv; 1997; 10(2-3):vii-x. PubMed ID: 10169229
[TBL] [Abstract][Full Text] [Related]
34. The generic drug approval process.
Rheinstein PH
Am Fam Physician; 1993 Dec; 48(8):1357-60. PubMed ID: 8249762
[No Abstract] [Full Text] [Related]
35. Generics still unable to resolve ANDA patent issues by declaratory judgment, but is a supreme court resolution on the way?
Eccleston LE
Health Care Law Mon; 2006 Dec; ():3-5. PubMed ID: 17236678
[No Abstract] [Full Text] [Related]
36. Staving off death: a case study of the pharmaceutical industry's strategies to protect blockbuster franchises.
Gorlin DI
Food Drug Law J; 2008; 63(4):823-64. PubMed ID: 19601385
[No Abstract] [Full Text] [Related]
37. Biogenerics standoff.
Herrera S
Nat Biotechnol; 2004 Nov; 22(11):1343-6. PubMed ID: 15529145
[No Abstract] [Full Text] [Related]
38. HIV drugs. New Congress could create hurdles for drug patents.
AIDS Policy Law; 2007 Jan; 22(2):5. PubMed ID: 17319014
[No Abstract] [Full Text] [Related]
39. Generic drugs: the stalling game.
Consum Rep; 2001 Jul; 66(7):36-40. PubMed ID: 11725791
[TBL] [Abstract][Full Text] [Related]
40. GATT implementation and generic drug approval.
Safir PO; Lassman SM
Food Drug Law J; 1996; 51(2):295-302. PubMed ID: 11820203
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
